Following on from information provided to NICE by the company in August 2022 the appraisal of Lasmiditan for treating acute migraine [ID3759] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | STA Standard |
| ID number | 3759 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 August 2023 | Discontinued. Following on from information provided to NICE by the company in August 2022 the appraisal of Lasmiditan for treating acute migraine [ID3759] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 18 August 2022 | Suspended. As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Lasmiditan for treating acute migraine. For information, the company have advised that they are no longer pursuing a Great Britain Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time due to the low likelihood of being deemed cost effective in England. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 26 March 2021 | The Department for Health and Social Care has asked NICE to conduct an appraisal of Lasmiditan within its marketing authorisation for treating acute migraine. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-May 2022. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 26 March 2021 | In progress. Topic is in progress |
| 21 January 2021 - 18 February 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual